New combo therapy aims to tame kidney disease
NCT ID NCT07038382
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug (HLX79) combined with an existing antibody treatment (rituximab) for people with active kidney inflammation called glomerulonephritis. About 24 adults with membranous nephropathy or lupus-related kidney disease will receive either the new drug or a placebo, plus rituximab. The goal is to see if the combination is safe and helps control the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUPUS NEPHRITIS (LN) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Tsinghua Changgung Hospital
NOT_YET_RECRUITINGBeijing, China
-
Guangdong Provincial People's Hospital
NOT_YET_RECRUITINGGuangzhou, China
-
Jiangsu Province Hospital
NOT_YET_RECRUITINGNanjing, China
-
Jiangxi Provincial People's Hospital
NOT_YET_RECRUITINGNanchang, China
-
Peking University People's Hospital
NOT_YET_RECRUITINGBeijing, China
-
Renmin Hospital Of Wuhan University
NOT_YET_RECRUITINGWuhan, China
-
Shanghai General Hospital
RECRUITINGShanghai, China
-
Su Bei People's Hospital
NOT_YET_RECRUITINGYangzhou, China
-
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
NOT_YET_RECRUITINGGuangzhou, China
-
The First Affiliated Hospital Of Xiamen University
NOT_YET_RECRUITINGXiamen, China
-
The First Affiliated Hospital Zhejiang University School Of Medicine
NOT_YET_RECRUITINGHangzhou, China
-
The First Affiliated Hospital of Henan University of Science and Technology
NOT_YET_RECRUITINGLuoyang, China
-
The First Affiliated Hospital of Nanchang University
NOT_YET_RECRUITINGNanchang, China
-
The First Affiliated Hospital of Xi'an Jiao Tong University
NOT_YET_RECRUITINGXi'an, China
-
The Second Hospital of Anhui Medical University
NOT_YET_RECRUITINGHefei, China
-
Xiangya Hospital Of Gentral South University
NOT_YET_RECRUITINGChangsha, China
-
Zhongdong Hospital Southeast University
NOT_YET_RECRUITINGNanjing, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can engineered immune cells tackle a tough kidney disease?
- Can a smarter antibody outsmart a kidney disease that resists standard treatment?
- Can engineered immune cells tame autoimmune kidney disease?
- Can a pill calm the immune attack on kidneys?
- Can a single infusion of reprogrammed immune cells quiet lupus kidney disease?
- Can a gene-silencing drug calm overactive complement in kidney disease?